R&D_R&D_Changchun GeneScience Pharmaceutical Co., Ltd.

Home
About Us 
Established in 1996, Changchun GeneScience Pharmaceutical Co., Ltd. (hereinafter referred to as ‘‘GenSci’) is one of the holding subsidiaries of Changchun High-tech (SZSE 000661)
Company Profile

Contact Us
Product 
Pharmaceutical

Medical Apparatus
R&D 
Pipeline and Therapeutic Fields

Key R&D Progress
Global Marketing
CSR

Please Enter Keywords To Search For Content

Close

CN

Home
About Us 
- Company Profile
- Contact Us
Product 
- Pharmaceutical
- Medical Apparatus
R&D 
- Pipeline and Therapeutic Fields
- Key R&D Progress
Global Marketing
CSR

1

Home

/

R&D





Key R&D Progress

Study May Proceed for Gentulizumab

2021-09-10

On December 18, 2020, Beijing time, GenSci’s Gentulizumab R&D project was approved by the US FDA for clinical trials, which means that this innovative therapy will soon proceed to clinical research in the United States. This is another milestone achievement following the approval of the project by the National Medical Products Administration (NMPA) for clinical trials in September of the same year.

The Gentulizumab injection is developed for advanced malignant solid tumors and lymphomas, as well as hematological malignancies. This is the first innovative biological drug approved by the FDA for clinical trials by GenSci, and shows that the technology and quality of GenSci's innovative R&D projects have reached the international standard.

On December 18, 2020, Beijing time, GenSci’s Gentulizumab R&D project was approved by the US FDA for clinical trials, which means that this innovative therapy will soon proceed to clinical research in the United States. This is another milestone achievement following the approval of the project by the National Medical Products Administration (NMPA) for clinical trials in September of the same year.

The Gentulizumab injection is developed for advanced malignant solid tumors and lymphomas, as well as hematological malignancies. This is the first innovative biological drug approved by the FDA for clinical trials by GenSci, and shows that the technology and quality of GenSci's innovative R&D projects have reached the international standard.